Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AWP Reform Debate Continues; U.S. Oncology Says Cut Will Hit Profits In ‘05

Executive Summary

U.S. Oncology expects that the transition from AWP-based reimbursement to ASP-based reimbursement will reduce Medicare payments to oncologists by approximately 8% in 2005

You may also be interested in...



U.S. Oncology To Go Private Ahead Of Medicare Part B Changes In 2005

U.S. Oncology plans to go private ahead of the 2005 reimbursement changes for chemotherapy drugs under the Medicare prescription drug law

U.S. Oncology To Go Private Ahead Of Medicare Part B Changes In 2005

U.S. Oncology plans to go private ahead of the 2005 reimbursement changes for chemotherapy drugs under the Medicare prescription drug law

Oncologists Seek Immediate Fixes To Medicare Part B Payment Rates

The American Society of Clinical Oncology is seeking legislation to create an "exceptions" process to ensure that Medicare Part B drug payments to oncologists cover drug acquisition costs

Related Content

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel